Expand LABT Menu
LABT MENU

LABT Latest Press Releases

-- September 24, 2026 --

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers PRNewswire 8:02 AM

-- September 21, 2026 --

Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3 PRNewswire 8:02 AM

-- September 18, 2026 --

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers PRNewswire 8:15 AM

-- September 8, 2026 --

Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference PRNewswire 8:02 AM

-- July 22, 2026 --

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria PRNewswire 8:02 AM

-- July 15, 2026 --

Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel PRNewswire 8:02 AM

-- July 7, 2026 --

Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance PRNewswire 8:02 AM

-- June 26, 2026 --

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing Globe Newswire 8:35 AM

-- June 25, 2026 --

Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers PRNewswire 8:02 AM

-- June 23, 2026 --

Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th Globe Newswire 8:35 AM

-- June 22, 2026 --

Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin Compounds Being Developed for High-Need Antimicrobial Infections PRNewswire 8:02 AM

-- June 16, 2026 --

Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum PRNewswire 8:02 AM

-- May 27, 2026 --

Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers PRNewswire 8:02 AM

-- May 18, 2026 --

Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers PRNewswire 8:02 AM

-- May 12, 2026 --

Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3 PRNewswire 8:02 AM

-- May 1, 2026 --

Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers PRNewswire 8:02 AM

-- April 28, 2026 --

Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors PRNewswire 7:33 AM
Market Data Delayed 15 Minutes